Skip to Content

Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care

Katriina Jalkanen, from Helsinki University Hospital, discusses the LITESPARK study results on belzutifan, a new drug for renal cell carcinoma (RCC), at ESMO 2024. Key findings include statistically significant progression-free survival (PFS) with belzutifan compared to everolimus and a higher response rate (22.7% vs. 3.5%). In addition belzutifan is well-tolerated and could be used in future treatment combinations or earlier lines an Addition to a Standard of Care.

Katriina Jalkanen

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top